Trials / Recruiting
RecruitingNCT07222709
A Study to Assess the Adverse Events and How Oral ABBV-1042 Moves Through the Body of Healthy Adult Participants
A Phase 1, Double-blind, Placebo-controlled, First-in-human Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of ABBV-1042 in Healthy Subjects
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This study will assess the adverse events, tolerability, and how oral ascending doses of ABBV-1042 moves through the body of healthy adult participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABBV-1042 | Oral Solution |
| DRUG | Placebo | Oral Solution |
Timeline
- Start date
- 2025-10-27
- Primary completion
- 2026-05-01
- Completion
- 2026-05-01
- First posted
- 2025-10-30
- Last updated
- 2025-10-30
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT07222709. Inclusion in this directory is not an endorsement.